Skip to main content
Dare Bioscience, Inc. logo

Dare Bioscience, Inc. — Investor Relations & Filings

Ticker · DARE ISIN · US23666P1012 US Manufacturing
Open in API
Filings indexed 732 across all filing types
Latest filing 2026-06-12 Declaration of Voting R…
Country US United States of America
Listing US DARE

About Dare Bioscience, Inc.

https://www.darebioscience.com/

Dare Bioscience, Inc. is a clinical-stage biopharmaceutical company focused on advancing innovative products for women's health. The company conducts end-to-end clinical development of therapies designed to address unmet needs in areas such as contraception, sexual health, vaginal health, and menopause. Its pipeline includes candidates like Ovaprene®, a hormone-free monthly contraceptive, and a topical sildenafil cream for female sexual arousal disorder. Dare Bioscience emphasizes a rigorous, science-based approach to develop medically credible and evidence-based solutions, aiming to close critical gaps in female healthcare.

Recent filings

Filing Released Lang Actions
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is a Form 8-K filed with the SEC, which typically reports significant corporate events. The text shows detailed results of voting at the 2026 annual meeting of stockholders, including election of directors, appointment of auditors, approval of compensation, stock incentive plan amendment approval, and other voting matters. This corresponds directly to an official disclosure of voting results from a shareholder meeting. It is not the proxy statement itself, nor an annual report. The document clearly states results for multiple proposals with vote counts and outcomes, which matches the definition of 'Declaration of Voting Results & Voting Rights Announcements (DVA)'. The length and content are consistent with an official vote result disclosure. Therefore, the correct classification is DVA with high confidence.
2026-06-12 English
DEFA14A
Proxy Solicitation & Information Statement
2026-06-01 English
DEFA14A
Proxy Solicitation & Information Statement
2026-06-01 English
8-K
Capital/Financing Update Classification · 92% confidence The document is a Form 8-K “Current Report” disclosing the closing of a Regulation A offering of equity securities (Series A Convertible Preferred Stock and warrants) and details of share issuance and fundraising. This is an update on a financing activity/ capital raise. Therefore, it should be classified under Capital/Financing Update (CAP).
2026-05-18 English
10-Q
Interim / Quarterly Report Q1 2026
2026-05-14 English
8-K
Regulatory Filings Classification · 93% confidence The document is a Form 8-K current report under the Securities Exchange Act, furnishing a press release on quarterly financial results via Exhibit 99.1. It does not contain the actual earnings data itself (the release is attached as an exhibit), nor is it the full interim report or a proxy or dividend notice. This is a compliance/regulatory filing announcing the release of results. Therefore it best fits the “Regulatory Filings” category (RNS).
2026-05-14 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.